Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone in advanced colorectal cancer
NCT03906565Phase 2Suspended
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Start
- Apr 2019
- Primary completion
- Dec 2023
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of utidelone in colorectal cancer (CRC), sponsored by Beijing Biostar Pharmaceuticals Co., Ltd. Primary endpoint: Tumor response to utidelone treatment at 6 months. Started Apr 2019; status: suspended.
02
Drugs
utidelone
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03906565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03906565.